ASCO: Ipilimumab Cuts Relapse but Safety Issues Remain
CHICAGO -- High-risk melanoma patients have a reduced level of relapse if they are taking the monoclonal antibody ipilimumab (Yervoy) when compared with placebo, researchers said here.
Jun 02, 2014